Sl no. | Descriptors | Thymol | Carvacrol | Cinnamaldehyde |
---|---|---|---|---|
Physicochemical properties | ||||
1. | SMILE | Cc1ccc(c(c1)O)C(C)C | CC(c1ccc(c(c1)O)C)C | O=CC=Cc1ccccc1 |
2. | Formula | C10H14O | C10H14O | C9H8O |
3. | Molecular weight (g/mol) | 150.22 | 150.22 | 132.16 |
4. | Number of heavy atoms | 11 | 11 | 10 |
5. | Number of aromatic heavy atoms | 6 | 6 | 6 |
6. | Fraction Csp3 | 0.40 | 0.40 | 0.00 |
7. | Number of rotatable bonds | 1 | 1 | 2 |
8. | Number of H-bond acceptors | 1 | 1 | 1 |
9. | Number of H-bond donors | 1 | 1 | 0 |
10. | Molar refractivity | 48.01 | 48.01 | 41.54 |
11. | Topological polar surface area (Ų) | 20.23 | 20.23 | 17.07 |
Lipophilicity | ||||
12. | Log Po/w (iLOGP) | 2.32 | 2.24 | 1.65 |
13. | Log Po/w (XLOGP3) | 3.30 | 3.49 | 1.90 |
14. | Log Po/w (WLOGP) | 2.82 | 2.82 | 1.79 |
15. | Log Po/w (MLOGP) | 2.76 | 2.76 | 2.01 |
16. | Log Po/w (SILICOS-IT) | 2.79 | 2.79 | 2.48 |
17. | Consensus log Po/w | 2.80 | 2.82 | 1.97 |
Water solubility | ||||
18. | Log S (ESOL) | − 3.19 | − 3.31 | − 2.17 |
19. | Solubility | 9.74e−02 mg/ml; 6.49e−04 mol/l | 7.40e−02 mg/ml; 4.92e-04 mol/l | 8.97e−01 mg/ml; 6.79e−03 mol/l |
20. | Class | Soluble | Soluble | Soluble |
21. | Log S (Ali) | − 3.40 | − 3.60 | − 1.88 |
22. | Solubility | 5.97e−02 mg/ml; 3.98e−04 mol/l | 3.79e−02 mg/ml; 2.53e−04 mol/l | 1.74e + 00 mg/ml; 1.31e−02 mol/l |
23. | Class | Soluble | Soluble | Very soluble |
24. | Log S (SILICOS-IT) | − 3.01 | − 3.01 | − 2.40 |
25. | Solubility | 1.46e-01 mg/ml; 9.71e−04 mol/l | 1.46e−01 mg/ml; 9.71e−04 mol/l | 5.26e−01 mg/ml; 3.98e−03 mol/l |
26. | Class | Soluble | Soluble | Soluble |
Pharmacokinetics | ||||
27. | GI absorption | High | High | High |
28. | BBB permeant | Yes | Yes | Yes |
29. | P-gp substrate | No | No | No |
30. | CYP1A2 inhibitor | Yes | Yes | No |
31. | CYP2C19 inhibitor | No | No | No |
32. | CYP2C9 inhibitor | No | No | No |
33. | CYP2D6 inhibitor | No | No | No |
34. | CYP3A4 inhibitor | No | No | No |
35. | Log Kp (skin permeation) (cm/s) | − 4.87 | − 4.74 | − 5.76 |
Drug-likeness | ||||
36. | Lipinski | Yes; 0 violation | Yes; 0 violation | Yes; 0 violation |
37. | Ghose | No; 1 violation: MW < 160 | No; 1 violation: MW < 160 | No; 2 violations: MW < 160, #atoms < 20 |
38. | Veber | Yes | Yes | Yes |
39. | Egan | Yes | Yes | Yes |
40. | Muegge | No; 2 violations: MW < 200, Heteroatoms < 2 | No; 2 violations: MW < 200, Heteroatoms < 2 | No; 2 violations: MW < 200, Heteroatoms < 2 |
41. | Bioavailability score | 0.55 | 0.55 | 0.55 |
Medicinal chemistry | ||||
42. | PAINS | 0 Alert | 0 Alert | 0 Alert |
43. | Brenk | 0 Alert | 0 Alert | 2 Alerts: aldehyde, michael_acceptor_1 |
44. | Lead likeness | No; 1 violation: MW < 250 | No; 1 violation: MW < 250 | No; 1 violation: MW < 250 |
45. | Synthetic accessibility | 1.00 | 1.00 | 1.65 |